EUVIMEDEUVIMED entdecken
Crossref

A Study to Explore the Role of IDH1 (R132) Mutation on Imatinib Toxicity and Effect of ABCG2/OCT1 Expression on N-Desmethyl Imatinib Plasma Level in Egyptian Chronic Myeloid Leukemia Patients

Alaa Sabri, Mervat M Omran, S Abdel Azim, Raafat Abdelfattah, Rasha Mahmoud Allam, Samia A Shouman

Drug Research · 01.03.2023 · 73 (03) · 146-155

DOI: 10.1055/a-1924-7746 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Research, erschienen am 01.03.2023. Verfasst von Alaa Sabri und 5 weiteren Autor:innen. Beteiligte Einrichtung: Egyptian Pharmaceutical Vigilance Center, Egyptian Drug Authority. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Antineoplastic Agents. Die Arbeit nennt 52 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Imatinib mesylate (IM) is the gold standard for treatment of Chronic Myeloid Leukemia (CML). This study aimed to gain more knowledge of the altered PK, pharmacogenetic factors, and gene expression leading to variable IM levels. Fifty patients with chronic phase-CML were enrolled in this study and divided as 25 responders and 25 non-responders (patients are directly recruited after response assessment). HPLC/MS/MS was used to determine trough and peak concentration of imatinib and N-desmethyl imatinib in the blood. PCR-RFLP technique was used to detect IDH1 gene mutation (R132). The median value of IM trough level was significantly higher, the P/T ratio was significantly lower and the α-1-acid glycoprotein (AGP) was significantly higher among responders compared to non-responders (P=0.007, 0.009 and 0.048, respectively). Higher N-desmethyl imatinib peak plasma concentration was observed with low mRNA expression of ABCG2 and OCT1 (P=0.01 and 0.037, respectively). IDH1 R132 gene mutation was associated with a significant increase in toxicities (P=0.028). In conclusion, IM trough level, P/T ratio and AGP was significantly higher in responders. In addition, ABCG2 and OCT1 gene expression may affect the interindividual PK variation. Although a prospective study with a larger patient population is necessary to validate these findings. IDH1 mutation is a predictor of increased toxicity with IM treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveAntineoplastic AgentsHumansImatinib MesylateTandem Mass SpectrometryEgyptProspective StudiesMutationATP Binding Cassette Transporter, Subfamily G, Member 2Neoplasm ProteinsIsocitrate Dehydrogenase

Substanzen

Imatinib MesylateAntineoplastic AgentsABCG2 protein, humanATP Binding Cassette Transporter, Subfamily G, Member 2Neoplasm ProteinsIDH1 protein, humanIsocitrate Dehydrogenase

Autor:innen und Institutionen

  • Egyptian Pharmaceutical Vigilance Center, Egyptian Drug Authority.
  • Pharmacology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
  • Biochemistry Department, Faculty of Pharmacy, Cairo University.
  • Medical Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
  • Cancer Epidemiology and Biostatistics Department, National Cancer Institute, Cairo University, Cairo, Egypt.

Zitieren

APA

Sabri, A., Omran, M. M., Azim, S. A., Abdelfattah, R., Allam, R. M., & Shouman, S. A. (2023). A Study to Explore the Role of IDH1 (R132) Mutation on Imatinib Toxicity and Effect of ABCG2/OCT1 Expression on N-Desmethyl Imatinib Plasma Level in Egyptian Chronic Myeloid Leukemia Patients. Drug Research, 73(03), 146-155. https://doi.org/10.1055/a-1924-7746

Vancouver

Sabri A, Omran MM, Azim SA, Abdelfattah R, Allam RM, Shouman SA. A Study to Explore the Role of IDH1 (R132) Mutation on Imatinib Toxicity and Effect of ABCG2/OCT1 Expression on N-Desmethyl Imatinib Plasma Level in Egyptian Chronic Myeloid Leukemia Patients. Drug Research. 2023;73(03):146-155. doi:10.1055/a-1924-7746

BibTeX
@article{Sabri2023,
  author = {Sabri, Alaa and Omran, Mervat M and Azim, S Abdel and Abdelfattah, Raafat and Allam, Rasha Mahmoud and Shouman, Samia A},
  title = {A Study to Explore the Role of IDH1 (R132) Mutation on Imatinib Toxicity and Effect of ABCG2/OCT1 Expression on N-Desmethyl Imatinib Plasma Level in Egyptian Chronic Myeloid Leukemia Patients},
  journal = {Drug Research},
  year = {2023},
  volume = {73},
  number = {03},
  pages = {146--155},
  doi = {10.1055/a-1924-7746}
}
Kostenlos starten →